Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Lexicon Pharmaceuticals (LXRX) Stock Price & Analysis

LXRX Stock Chart & Stats

$1.42-$0.00(-0.35%)
At close: 11:28 AM EST
$1.5$2$2.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$1.38 - $1.50
52-Week Range
$1.10 - $2.68
Previous Close
$1.48
Volume
N/A
Average Volume (3M)
2.60M
Market Cap
$631.84M
Enterprise Value
$919.00M
Total Cash (Recent Filing)
$190.61M
Total Debt (Recent Filing)
$59.28M
Price to Earnings (P/E)
―
Beta
1.73
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-0.06
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Deleveraged Balance Sheet

The move to zero debt and higher equity reduces financial risk and gives Lexicon greater flexibility to fund clinical development and commercialization. Although profitability remains unresolved, improved capitalization can support execution and reduce dependence on immediate refinancing while key programs advance.

SONATA-HCM Clinical Progress

Completing and significantly over-enrolling a pivotal Phase III study strengthens the evidence-generation process for Lexicon’s HCM program and may improve statistical power. This creates a defined value inflection and supports the durability of the late-stage pipeline over the next several quarters.

Zynquista Regulatory Advancement

Progress toward satisfying FDA exposure requirements and resubmitting the Zynquista NDA moves the program closer to a potential regulatory decision. That advancement could expand Lexicon’s commercial opportunity and create a clearer path from clinical investment to product revenue.

Bears Say

Persistent Cash Burn

Continued negative operating and free cash flow means Lexicon is not yet funding operations internally and must rely on existing liquidity or external financing. Persistent burn can constrain investment choices and increase dilution or financing pressure if clinical timelines extend or milestones are delayed.

Highly Volatile Revenue Base

The sharp recent revenue contraction highlights how dependent reported results are on irregular commercialization or partner-related receipts rather than a stable recurring base. Such volatility makes forward revenue less predictable and leaves funding capacity sensitive to licensing timing and milestone events.

Persistent Unprofitability And Rising Costs

Lexicon’s strong gross margin does not offset its operating cost base, leaving the company persistently loss-making while investment requirements rise. Sustained R&D and commercial preparation spending may be necessary for pipeline progress, but it also delays breakeven and prolongs reliance on financing.

Lexicon Pharmaceuticals News

LXRX FAQ

What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $1.10 and its highest was $2.68 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $631.84M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 3 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.02.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.06.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,955,930 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.673%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Hedge funds hold Lexicon Pharmaceuticals shares: the largest hedge-fund position in Lexicon Pharmaceuticals is 71,885,672 shares, and hedge funds increased their holdings by 14.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology